Lancet Haematology

Article	Citations
Towards reparatory measures: blood donation, health systems, and men who have sex with men	215
A new player in IDH1 mutated myeloid neoplasias	212
Pegcetacoplan: climbing up the complement cascade	181
Risk stratification for Down syndrome and acute lymphocytic leukaemia: one size does not fit all	170
Lines of the haematology community	150
Correction to Lancet Haematol 2025; 12: e109–19	139
Long-term neurodevelopmental outcomes in infants with haemolytic disease of the newborn treated with darbepoetin	138
Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial	129
Epistemic limitations of measurable residual disease in haematological malignancies	129
Low-dose aspirin versus placebo in postpartum venous thromboembolism: a multi-national, pilot, randomised, placebo-controlled trial	111
Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trial	111
Allogeneic haematopoietic stem-cell transplantation versus gene therapy for haemoglobinopathies	110
Orla McCourt—making space for proactive rehabilitation in haematology	103
Making blood count	97
The value of teaching the influence of sex and gender on health outcomes	95
Further investment for cancer reduction in the USA	95
Mitapivat for treatment of pyruvate kinase deficiency	93
Reducing toxic waste: improving toxicity capture in childhood cancer	92
Have cancer, will travel	87
Using immunogenetics to inform immunotherapy of lymphoid malignancies	82
A century between pandemics and poisonings	79
Future role of topical pimecrolimus in early stage mycosis fungoides?	77
Retinopathy associated with severe thrombocytopenia	76
Filling the data gaps on sickle cell anaemia in sub-Saharan Africa	76
Haploidentical bone marrow transplantation for severe aplastic anaemia: looking to the future	76

Neutrophil-erythrocyte rosettes suggestive of Coombs-negative autoimmune haemolysis	69
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study	68
Oleksandr Lysytsia: the war in Ukraine has changed everything about our lives	68
Improved survival and enhanced quality of life through anaemia correction in lower risk myelodysplastic syndromes: meaningful insights from an EUMDS Registry study	66
Haematology's role on the path to health for all Africans	65
A+AVD versus eBEACOPP in advanced-stage Hodgkin lymphoma	65
A comprehensive approach to therapy of haematological malignancies in older patients	63
Packed red blood cell transfusion in preterm infants	61
Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issues	61
Alloimmunisation against red blood cells in sickle cell disease: transfusion challenges in high-income and low-income countries	60
Will the changing therapeutic landscape meet the needs of patients with sickle cell disease?	59
Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity?	58
Diagnostic evaluation of paediatric autoimmune lymphoproliferative immunodeficiencies (ALPID): a prospective cohort study	58
Modelling the mortality of sickle cell disease in Africa	57
Regional empowerment through decentralised governance under a centralised regulatory system facilitates the development of cellular therapy in China	56
All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial	55
Immunochemotherapy for life-threatening haematological malignancies in pregnancy: a systematic review of the literature and cross-sectional analysis of clinical trial eligibility	54
Consideration of ATG-free therapy with eltrombopag and cyclosporine for severe aplastic anaemia	53
First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial	53
The effects of upward revision of haemoglobin thresholds for anaemia in blood donations – Authors' reply	53
Vaccine efficacy and iron deficiency: an intertwined pair?	52
Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial	51
Trends, opportunities, and challenges of clinical trials for haematological diseases in China	50
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial	50
Prioritising health equity alongside donation safety – Authors' reply	47
Retinal haemorrhage as a complication of blastic plasmacytoid dendritic cell neoplasm	47
Improving the global reporting of multiple myeloma: a focus on low-income and middle-income countries	46
Prehospital blood transfusion for haemorrhagic shock	45
Sex specific definitions of anaemia reflect androgen production – Authors' reply	45
Prehospital blood transfusion for haemorrhagic shock	45
Lower strength stockings: is less better?	44
ISTH 2021 Congress	44
In the trenches	43
Ultra-low-dose radiation for gastric MALT lymphoma	43
Challenges in haemophilia care in the Philippines	43
On the basis of sex: outcomes in myelodysplastic syndromes	42
Thrombopoietin receptor agonist in chemotherapy-induced thrombocytopenia	42
COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria	41
Optimising maintenance therapy after transplantation: sorafenib's role in patients with FLT3-ITD acute myeloid leukaemia	41
European Hematology Association 2023 Hybrid Congress	40
Factors to consider when assessing the IDOCS study – Authors’ reply	40
Managing haematological malignancies in pregnant women	40
Ruxolitinib: a game changer in paediatric chronic graft-versus-host disease management?	39
Defining global thresholds for anaemia: a challenging mission	39
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study	39
Tackling the enormous global burden of anaemia	39
“I can't breathe”: how sickle cell disease manifests in the USA today	38
Celebrating blood donors amid advances in blood transfusion	38
Aaron Goodman: “people tell me they've been waiting for someone to speak up”	38
Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies	38

Appropriate use of sex and gender for diversity, equity, and inclusion in biomedical research	37
Nelarabine and optimisation of therapy for T-cell acute lymphoblastic leukaemia	36
Association between maternal haemoglobin concentrations and maternal and neonatal outcomes: the prospective, observational, multinational, INTERBIO-21st fetal study	36
CAR T-cell therapy for multiple myeloma: state of the art and prospects	36
Clinical implications and insights from patient-reported outcome data in KarMMa-3	35
Incidence and prognosis of superficial vein thrombosis during pregnancy and the post-partum period: a Danish nationwide cohort study	35
Multimodal intervention for preventing peripheral intravenous catheter failure in adults (PREBACP): a multicentre, cluster-randomised, controlled trial	35
Antifibrinolytics do not add to the benefits of platelet transfusion	35
Patient-reported outcomes: important data in early trials of novel therapies	34
Low-dose dasatinib: when less can be more	33
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts	33
Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis	33
Zanubrutinib-associated ecchymotic lesions	33
Eltrombopag–cyclosporin A in treating severe aplastic anaemia – Authors' reply	32
Trials and tribulations: including women in cancer clinical research	32
High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial	32
Step out of the shadows: a call for action for rare diseases	32
Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial	32
Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?	30
Diversity, equity, and inclusion in ASH guidelines – Authors’ reply	30
Novel strategies in the treatment of acute lymphoblastic leukaemia	30
Sexual health-related psychological and emotional life after allogeneic haematopoietic stem-cell transplantation	29
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network	29
Improving quality of blood transfusion practices in Nigeria	29
Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial	29
A comprehensive view of pregnancy in patients with sickle cell disease in high-income countries: the need for robust data and further decline in morbidity and mortality	29
Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial	28
The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA	28
Diagnosis, treatment, and surveillance of Diamond-Blackfan anaemia syndrome: international consensus statement	28
Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial	27
Frontline treatment of adults with newly diagnosed B-cell acute lymphoblastic leukaemia	26
Correction to Lancet Haematol 2023; 10: e333–45	25
Correction to Lancet Haematol 2023; published online Aug 28. https://doi.org/10.1016/S2352-3026(23)00164-3	25
Everyone is a potential lifesaving stem cell donor	25
Correction to Lancet Haematol 2023; 10: e333–45	25
Correction to Lancet Haematol 2023; 10: e492–94	25
Correction to Lancet Haematol 2024; 11: e114–26	25
Correction to Lancet Haematol 2023; 10: e419–32	24
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial	23
Haematological malignancies in sub-Saharan Africa: east Africa as an example for improving care	23
Obiageli Nnodu: sickle cell disease in Africa's largest nation	23
GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial	23
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3	23
Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial	22
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial	22
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study	22
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose e	21
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, mult	21
Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial	21
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study	21
Current status of phase 3 clinical trials in high-risk myelodysplastic syndromes: pitfalls and recommendations	21
Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?	21
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial	21
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial	20
Fedratinib for patients with myelofibrosis – Authors’ reply	20
Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions	20
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: lon	20
MRD-guided treatment cessation in multiple myeloma	20
Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions	20
Social determinants of health: the next frontier for improving care and outcomes in sickle cell disease	20
Should we screen for plasma cell dyscrasias in people with low bone density?	19
Let's talk about sex and haematopoietic stem-cell transplantation	19
Vaccine-induced immune thrombotic thrombocytopenia	18
Sexually transmitted infections in the context of haematological malignancies	18
Blood deserts: a vision to tackle blood inaccessibility	18
Sex and gender reporting in high impact haematology journals	17
Production and supply of blood products in Brazil	17
Be compliant or compromise?	17
Thrombotic risk and features of patients with inferior vena cava agenesis: a multicentre, retrospective, observational study	17
Choosing the ideal immunotherapy for high-risk ALL	16
CAR T cells in CNS-relapsed leukaemia: one step forward	16
Lallindra Gooneratne—maintaining treatment flow amid crisis	16
Painting the place where procedures cause pain	16
Thrombotic complications of immune thrombocytopenic purpura	16
Venetoclax with intensive chemotherapy in younger patients with acute myeloid leukaemia	16
Sequencing therapies in Hodgkin lymphoma	15
The HemeOncBuddy app—a new tool to keep up with the clinical trial storm	15
Rosline Hassan: building the future of haemato-pathology in Malaysia	15
Bedside art is good medicine	14
Climate change and haematology: perspectives from the Philippines	14

Elotuzumab: no benefit for older patients with newly diagnosed multiple myeloma	14
Artwork from trauma: the social life of medical data	14
The evolving multi-agent options for chronic lymphocytic leukaemia treatment	13
Meeting the health needs of people from Afghanistan	13
A roadmap during parenting	13
Sickle cell disease: a year in review	13
Rahul Bhargava: making bone marrow transplantation accessible in India	13
Sex specific definitions of anaemia reflect androgen production	13
Optical or optimal conclusion: pharmacokinetic-guided dosing in haemophilia	12
SintraREViewed: practice changing, or validation required?	12
Am I a scientist?	12
Understanding the barriers to AML care in India	12
EHA 2021 Virtual Congress	12
Correction to Lancet Haematol 2021; 8: e55–66	12
A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study	12
Use of darbepoetin alfa in haemolytic disease of the fetus and newborn	11
Racial and ethnic survival disparities in patients with haematological malignancies in the USA: time to stop ignoring the numbers	11
Impostors out!	11
Blinatumomab plus hyper-CVAD: the prelude to a new era in acute lymphocytic leukaemia	11
The dawn of the CRISPR/Cas9 gene therapy era	10
Do we need another TKI for chronic myeloid leukaemia?	10
What we now BELIEVE is achievable with luspatercept in transfusion-dependent β-thalassaemia	10
All systems are not GO: ongoing challenges in interpreting gemtuzumab ozogamicin clinical trial results – Authors' reply	10
Thromboprophylaxis in paediatric acute lymphoblastic leukaemia	10
A probable case of aggressive extranodal natural killer T-cell lymphoma in a 19th century Qing Dynasty painting	10
Against all odds	10
Accelerating Action for women's equality	10
The story of my zebra	9
Call to action: equitable comprehensive care for patients with sickle cell disease in the USA	9
FIT for surgery: fractures, iron, and tranexamic acid	9
International Society on Thrombosis and Haemostasis Congress 2023	9
Non-replacement therapy for people with haemophilia B: another step towards health equity	9
CPX-351 for higher risk myelodysplastic syndrome: cytarabine and daunorubicin in disguise?	8
Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review	8
Sustained prothrombotic changes in convalescent patients with COVID-19	8
Correction to Lancet Haematol 2022; 9: e563–72	8
COVID-19 vaccines: building and maintaining confidence	8
Álvaro Urbano-Ispizua—a more accessible last chance for patients	8
Estimating the risk of child mortality attributable to sickle cell anaemia in sub-Saharan Africa: a retrospective, multicentre, case-control study	8
Increasing availability of oral therapy in haematology	8
Correction to Lancet Haematol 2024; 11: e27–37	8
Sickle cell disease strategies and priorities	8
Correction to Lancet Haematol 2024; 11: e862–72	8
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, p	8
Correction to Lancet Haematol 2023; 10: e433–44	8
Factors to consider when assessing the IDOCS study	8
Reactivating hope for TP53-mutated acute myeloid leukaemia?	7
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study	7
Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group	7
Iron deficiency in women: clearing the rust of silence	7
Living with sickle cell disease: voices from sub-Saharan Africa	7
Endemic or regionally limited parasitic and fungal infections in haematopoietic stem-cell transplantation recipients: a Worldwide Network for Blood and Marrow Transplantation (WBMT) Review	7
Control participants of randomised trials: an often forgotten, vulnerable population	7
How does zanubrutinib fare in treatment of B-cell malignancies?	7
COVID-19 vaccines for patients with haematological conditions	7
An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes	7
Update on SickleInAfrica: a collaborative and multidimensional approach to conduct research and improve health	7
UK changes LGBT+ blood donation rules but Africa restriction remains	7
Pembrolizumab plus single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma	7
Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial	7
Haematology in sub-Saharan Africa: advances and opportunities in health care, education, and research	6
Melflufen: post-hoc subgroup analyses and the US FDA Oncologic Drugs Advisory Committee	6
Blood cell defence against pathogens	6
Eltrombopag–cyclosporin A in treating severe aplastic anaemia	6
Correction to Lancet Haematol 2022; 9: e361–73	6
Long-term data from the REACH study testing hydroxyurea to treat sickle cell anaemia in children in sub-Saharan Africa	6
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 tr	6
Giving hereditary haemorrhagic telangiectasia the attention it deserves	6
Emicizumab for non-severe haemophilia A	6
Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, random	6
Time to define and refine maintenance strategies in acute myeloid leukaemia	6
Idiopathic multicentric Castleman disease with arteriolar endotheliopathy and secondary haemophagocytosis	6
Alexis Thompson: advancing care for sickle cell disease	6
Melflufen in multiple myeloma: the conclusion matters – Authors' reply	6
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study	6
Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study	6
Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past	6
Long term strategies for individuals with sickle cell disease	6
Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the U	6
From residency training to professional life: which competencies and skills are most valued by haematologists in Brazil?	6
Risk factors associated with venous and arterial neonatal thrombosis in the intensive care unit: a multicentre case-control study	6
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study	6
An integrated approach to cardioprotection in lymphomas	5
Conditioning regimens for HSCT for patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukaemia	5
Correction to Lancet Haematol 2023; 10: e203–12	5
25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): a randomised, double-blind, non-inferiority trial	5
Sex specific definitions of anaemia contribute to health inequity and sociomedical injustice	5
Surviving the storm: critical care outcomes of chimeric antigen receptor T-cell therapy	5
Iron deficiency anaemia—an ongoing challenge	5
Correction to Lancet Haematol 2021; 8: e205–15	5
Re-energising therapy options in sickle cell disease: the mitapivat phase 2 trial results	5
Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study	5
Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Workin	5
Correction to Lancet Haematol 2023; 10: e213–24	5
Sickle cell disease in India: current status and progress	5